We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
+77.51%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$170M
AUM Growth
+$29.8M
Cap. Flow
+$10.3M
Cap. Flow %
6.04%
Top 10 Hldgs %
84.84%
Holding
32
New
4
Increased
11
Reduced
6
Closed
3

Top Buys

Rank Stock Value
1
ANTX icon
AN2 Therapeutics
ANTX
+$9.98M
2
WHWK
Whitehawk Therapeutics
WHWK
+$3.23M
3
ACHL
Achilles Therapeutics
ACHL
+$2.78M
4
ADVM
Adverum Biotechnologies
ADVM
+$2.19M
5
ORMP icon
Oramed Pharmaceuticals
ORMP
+$2.04M

Top Sells

Rank Stock Value
1
TECX
Tectonic Therapeutic
TECX
+$4.65M
2
LONA
LeonaBio Inc
LONA
+$2.38M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$2.29M
4
DSGN icon
Design Therapeutics
DSGN
+$1.41M
5
TIL icon
Instil Bio
TIL
+$1.32M

Sector Composition

Rank Sector Weight
1 Healthcare 73.51%
2 Technology 1.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGOV icon
1
iShares 0-3 Month Treasury Bond ETF
SGOV
$97.5B
$27.2M 16%
270,000
– –
TIL icon
2
Instil Bio
TIL
$50.9M
$22.6M 13.27%
335,000
-56,103
-14% -$1.32M
AVIR icon
3
Atea Pharmaceuticals
AVIR
$377M
$22.3M 13.11%
6,650,000
+274,379
+4% +$995K
ACRS icon
4
Aclaris Therapeutics
ACRS
$749M
$16.4M 9.64%
14,250,000
+1,261,866
+10% +$1.55M
BIL icon
5
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.8B
$16.1M 9.45%
175,000
-25,000
-13% -$2.29M
ADVM
6
DELISTED
Adverum Biotechnologies
ADVM
$15.9M 9.37%
2,268,064
+302,064
+15% +$2.19M
TECX
7
Tectonic Therapeutic
TECX
$578M
$6.42M 3.78%
211,752
-254,295
-55% -$4.65M
ANTX icon
8
AN2 Therapeutics
ANTX
$168M
$6.15M 3.62%
+5,749,432
New +$9.98M
OKUR
9
OnKure Therapeutics
OKUR
$166M
$5.88M 3.46%
345,740
+78,521
+29% +$1.16M
ORMP icon
10
Oramed Pharmaceuticals
ORMP
$166M
$5.33M 3.14%
2,186,191
+837,153
+62% +$2.04M
ACHL
11
DELISTED
Achilles Therapeutics
ACHL
$4.18M 2.46%
4,100,002
+3,474,828
+556% +$2.78M
WHWK
12
Whitehawk Therapeutics
WHWK
$192M
$4.12M 2.42%
+2,000,000
New +$3.23M
CNTB
13
Connect Biopharma Holdings
CNTB
$147M
$3.01M 1.77%
2,093,232
+49,984
+2% +$61K
PMVP icon
14
PMV Pharmaceuticals
PMVP
$69.3M
$2.52M 1.48%
1,688,772
+379,375
+29% +$586K
ASTC icon
15
Astrotech Corp
ASTC
$15.1M
$1.76M 1.04%
220,410
– –
MIST icon
16
Milestone Pharmaceuticals
MIST
$154M
$1.73M 1.02%
1,136,091
+33,196
+3% +$48.3K
LENZ
17
LENZ Therapeutics
LENZ
$153M
$1.42M 0.84%
60,000
-3,916
-6% -$86.9K
IMA
18
ImageneBio Inc
IMA
$61.5M
$1.25M 0.74%
60,274
+11,514
+24% +$233K
VNDA icon
19
Vanda Pharmaceuticals
VNDA
$328M
$1.07M 0.63%
228,500
-169,780
-43% -$910K
LSTA icon
20
Lisata Therapeutics
LSTA
$31.9M
$854K 0.5%
284,669
– –
PVLA
21
Palvella Therapeutics
PVLA
$2.12B
$699K 0.41%
+42,130
New +$616K
CALC icon
22
CalciMedica
CALC
$11M
$682K 0.4%
153,887
-6,537
-4% -$28.7K
KLRS
23
Kalaris Therapeutics
KLRS
$110M
$488K 0.29%
26,221
– –
TLIS
24
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$460K 0.27%
248,702
+205,959
+482% +$1.4M
VTGN icon
25
VistaGen Therapeutics
VTGN
$9.85M
$452K 0.27%
150,000
– –
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
TI
Truxt Investmentos Rio De Janeiro, Brazil $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
IWA
Invera Wealth Advisors Bend, Oregon $156M AUM 22.76% 1-Year Est. Return
PFO
Pioneer Family Office North Miami Beach, Florida $156M AUM
HCWM
Hidden Cove Wealth Management Bainbridge Island, Washington $156M AUM 16.51% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return

BML Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, BML Capital Management held 32 positions worth $170M, up 21% from $140M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

BML Capital Management deployed $10.3M of net new capital in Q3 2024, opening 4 new positions and adding to 11 existing holdings. Its largest new stake was AN2 Therapeutics: 5,749,432 shares worth $6.15M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 64% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Tectonic Therapeutic, an estimated $4.65M trimmed.

  • BML Capital Management's largest Q3 2024 buy was AN2 Therapeutics: 5,749,432 shares worth $6.15M.
  • BML Capital Management added most to Achilles Therapeutics in Q3 2024, an estimated $2.78M increase.
  • BML Capital Management's biggest Q3 2024 reduction was Tectonic Therapeutic, cutting an estimated $4.65M.
  • BML Capital Management fully exited LeonaBio Inc in Q3 2024, selling an estimated $2.38M.
  • BML Capital Management's ten largest holdings make up 85% of its $170M portfolio in Q3 2024.
  • BML Capital Management opened 4 new positions and closed 3 in Q3 2024.
  • BML Capital Management's portfolio value rose 21% quarter-over-quarter to $170M.

Based on BML Capital Management's 13F filing for Q3 2024, filed 5 Nov 2024.